1. Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014; 34:115–122. PMID:
24879977.
Article
2. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129:512–521. PMID:
16083708.
Article
3. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology. 2004; 40:773. PMID:
15382161.
Article
4. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995; 58:108–117. PMID:
7628177.
Article
5. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354:731–739. PMID:
16481640.
Article
6. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008; 135:1924–1934. 1934.e1–1924. PMID:
18955056.
Article
7. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A, et al. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014; 147:109–118.e5. PMID:
24704526.
Article
8. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015; 148:1340–1352.e7. PMID:
25754159.
9. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014; 109:950–966. PMID:
24935270.
Article
10. Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol. 2014; 13:248–255. PMID:
24552867.
Article
11. Chalasani N, Regev A. Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage? Gastroenterology. 2016; 151:1046–1051. PMID:
27765688.
Article
12. Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007; 102:2437–2443. PMID:
17662100.
Article
13. Tan EH, Low EX, Dan YY, Tai BC. Systematic review and meta-analysis of algorithms used to identify drug-induced liver injury (DILI) in health record databases. Liver Int. 2018; 38:742–753. PMID:
29193566.
Article
14. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011; 89:806–815. PMID:
21544079.
Article
15. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46:1323–1330. PMID:
8229110.
Article
16. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11:272–276. PMID:
2254635.
17. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004; 58:71–80. PMID:
15206996.
Article
18. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006; 24:1187–1195. PMID:
17014577.
Article
19. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144:1419–1425. 1425.e1–1413. PMID:
23419359.
Article
20. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002; 36:451–455. PMID:
12143055.
Article
21. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012; 107:1380–1387. PMID:
22733303.
Article
22. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005; 61:135–143. PMID:
15726344.
Article
23. Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006; 15:241–243. PMID:
16552790.
Article
24. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005; 42:481–489. PMID:
16025496.
Article
25. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Drug-induced liver injury: premarketing clinical evaluation: July 2009. Silver Spring: U.S. Food and Drug Administration;2019. cited 2019 Apr 19. Available from:
https://www.fda.gov/downloads/guidances/UCM174090.pdf.
26. Hunt CM. Expanding our toolkit to better identify drug-induced liver injury in electronic medical records. Liver Int. 2018; 38:585–587. PMID:
29575769.
Article
27. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991; 266:2847–2851. PMID:
1942452.
Article
28. Tegeder I, Levy M, Muth-Selbach U, Oelkers R, Neumann F, Dormann H, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol. 1999; 47:557–564. PMID:
10336581.
Article
29. Sistanizad M, Peterson GM. Drug-induced liver injury in the Australian setting. J Clin Pharm Ther. 2013; 38:115–120. PMID:
23350857.
Article
30. Cheetham TC, Lee J, Hunt CM, Niu F, Reisinger S, Murray R, et al. An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data. Pharmacoepidemiol Drug Saf. 2014; 23:601–608. PMID:
24920207.
Article
31. Bagheri H, Michel F, Lapeyre-Mestre M, Lagier E, Cambus JP, Valdiguié P, et al. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol. 2000; 50:479–484. PMID:
11069443.
Article
32. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol. 2010; 105:2396–2404. PMID:
20648003.
Article
33. Björnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol. 2017; 52:617–623. PMID:
28276834.
Article
34. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000; 31:201–206. PMID:
10613746.
Article
35. Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology. 2011; 54:1344–1350. PMID:
21735470.
Article